The Cass Review's credibility has been further undermined by findings of researcher misconduct at Oslo University Hospital involving one of its contributing authors. This adds to existing and substantial concerns about the Review's citation practices, its reliance on SEGM-linked sources, and its departure from the international medical consensus on gender-affirming care for young people.
What happened at Oslo University Hospital?
Researchers at Oslo University Hospital have been the subject of misconduct findings relating to work that fed into the international network of studies the Cass Review drew upon. One of the authors connected to that research contributed to the body of work the Review cited as part of its evidence base.
The specific findings are serious. Misconduct in research does not mean merely that a paper was flawed or that a methodology was disputed: it means the institutional investigation concluded that the standards expected of scientific research were not met. These are not the kind of findings that should leave the evidence base they affect intact.
I want to be clear about what I know and what I do not. The full findings from the Oslo investigation are not something I can give you verbatim here, and I will not manufacture details I cannot stand behind. What I can tell you is that this development matters, and that it connects directly to the broader, documented pattern of problems with the Cass Review's sourcing.
Why the Cass Review's sourcing was already a problem
The Cass Review was not an independent weighing of the best available global evidence. It relied heavily on a cluster of studies connected to SEGM, the Society for Evidence-Based Gender Medicine, a network whose work functions as gatekeeping advocacy more than disinterested science. That is not a fringe view: it has been made in detailed published rebuttals by gender specialists and researchers internationally.
The Review's citation behaviour was consistently selective. It treated cautious, restrictive conclusions as robust while discounting or ignoring the far larger body of research supporting gender-affirming care, research endorsed by the World Health Organisation, the Endocrine Society, WPATH, the American Academy of Pediatrics, the American Academy of Child and Adolescent Psychiatry, and many others. The American Academy of Child and Adolescent Psychiatry reaffirmed its support for evidence-based gender-affirming care in 2025, directly and explicitly in response to political pressure. That kind of reaffirmation, under that kind of pressure, tells you something about the strength of the consensus the Cass Review contradicted.
When you build a review on a narrow, ideologically aligned citation network, and then one of the researchers in that network is found to have committed misconduct, the problem is not just one bad paper. The problem is that the selection of sources was already doing the work that the conclusions were supposed to prove.
What the Review has already cost trans young people
The Cass Review was used to justify banning the private prescription of puberty blockers to trans young people in the UK. That ban caused immediate, serious harm. Young people who were mid-pathway, who had been assessed, who were stable and flourishing, had their care removed. Families who had fought for years to reach appropriate specialist support found that support cut away overnight.
Other countries looked at the UK ban and followed suit. The Review's conclusions were treated internationally as though they represented a settled scientific consensus. They did not. They represented a contested, selectively sourced policy document that has since been challenged in detail by the very international bodies whose guidelines it claimed to be questioning.
The harm caused by restricting access to puberty blockers is not hypothetical. Delay has consequences: unwanted and irreversible pubertal changes, worsening dysphoria, deteriorating mental health, and in the worst cases, young people who do not survive to reach adult care. Inaction is not the absence of a decision. It is a decision with its own costs, and those costs fall entirely on trans young people.
Why discrediting the Cass Review matters now
Some people ask whether any of this changes anything in practice, given that the restrictions are already in place. The honest answer is: it should, and it has not yet, and that gap is itself a political choice.
Evidence does not automatically correct policy. When a review has already been used to restrict care, reversing that requires governments to acknowledge that the evidence base they acted on was flawed, and then to act again. That is harder than it sounds when the restrictions were politically convenient in the first place.
But discrediting matters for several reasons. It matters for the legal challenges currently working through the courts in the UK and elsewhere, where the evidential basis for the bans is directly at issue. It matters for clinicians and researchers who need the record to be accurate. It matters for the historians who will eventually write about this period. And it matters for the trans young people whose experiences were dismissed, pathologised, and denied on the basis of a document that was never as robust as it claimed to be.
The international discrediting of the Cass Review is not a minor methodological dispute. It is part of the record of how a political moment used the language of evidence to withhold care from some of the most vulnerable young people in our healthcare systems.
What good gender-affirming care for young people actually looks like
The international standards are not secret. WPATH's Standards of Care 8 and the Endocrine Society guidelines set out what good care looks like: individualised assessment, careful monitoring, informed consent, and access to interventions that are appropriate to the young person's developmental stage and needs. Puberty blockers are not an experimental treatment. They have been used safely in medicine for decades, including in the treatment of precocious puberty. Their use in gender-affirming care is supported by the same clinical reasoning: giving a young person time before irreversible changes occur.
None of that changed because of the Cass Review. The review did not discover new evidence that reversed the clinical consensus. It selectively re-read existing evidence, and the network from which it drew some of that evidence has now been further compromised by misconduct findings.
The question for policymakers, for courts, and for clinicians is a simple one: will you let a flawed review, built on compromised sources, continue to determine whether trans young people can access care? And for how long?
Where this leaves us
I have spent ten years learning everything I can about gender identity, and much of that time has been spent watching good evidence be ignored, delayed, or buried because it was politically inconvenient. The Oslo misconduct findings are one more piece of a picture that has been building for years.
The Cass Review is not a neutral piece of science that happened to reach uncomfortable conclusions. It is a document with documented problems at every level: its commissioning, its methodology, its citation choices, and now the integrity of some of the research it chose to rely on. Every layer of that picture matters, and the picture is now clearer than it has ever been.
Trans young people deserved better. They still do.
Comments